Publication at First Faculty of Medicine |
2017
Abstract
Cetuximab is a mainstay of targeted therapy of metastatic colorectal carcinoma. Adding cetuximab to chemotherapy lead to significant prolongation of ove-r-all survival of patients without RAS gene mutations in clinical trials.
Moreover, cetuximab treatment was associated with significant early reduction in metastatic lesion load, making subsequent surgical resection possible. Our case studies demonstrate these benefits associated with cetuximab in clinical practice.